Skip to content

Decitabine Combination with Individualized Therapy of Traditional Chinese Medicine for the Treatment of Myelodysplastic Syndrome: A Multicenter Randomized Controlled Trial

Decitabine Combination with Individualized Therapy of Traditional Chinese Medicine for the Treatment of Myelodysplastic Syndrome: A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ONN-16009534
Enrollment
Unknown
Registered
2016-10-24
Start date
2017-01-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndrome

Interventions

western medicine:DAC
combine traditional Chinese and western medicine:DAC with Individualized Therapy of Traditional Chinese Medicine
Sequential combination of traditional Chinese and Western Medicine:Individualized Therapy of Traditional Chinese Medicine after DAC

Sponsors

Shanghai Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. Meet the diagnostic criteria of myelodysplastic syndrome (MDS) of conventional medicine; Meet the diagnostic criteria of syndrome in traditional Chinese medicine and be confirmed by two senior experts; 3. Two Chinese experts with advanced professional title major in blood disease; 4. Symptomatic anemia with no del(5q), serum EPO=500U/mL, no response to EPO; Symptomatic anemia with no del(5q), serum EPO=500U/mL, no response to IST; clinically relevant thrombocytopenia or neutropenia or increased marrow blasts; high risk MDS.

Exclusion criteria

Exclusion criteria: 1. Patients of secondary MDS; 2. Patients of 5q-; 3. Previously treated with methylation; 4. Complicated with other hematologic or non-hematologic tumor; 5. Complicated with serious organic lesion in heart, liver or kidney; 6. Patients during pregnancy or lactation; 7. Patients surffering from mental disorder; 8. Patients of category A or B infectious disease.

Design outcomes

Primary

MeasureTime frame
hemoglobin;neutrophil;platelet;

Countries

China

Contacts

Public ContactJiahui Lu

Shanghai Hospital of Traditional Chinese Medicine

lujiahui73@163.com+86 13601759004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026